{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 50 of 92', 'CR845-CLIN3102', 'Any worsening (ie, clinically significant change in frequency, nature, and/or', 'intensity) of a pre-existing condition.', 'A pre-existing condition is a condition that is present prior to signing the ICF for the', 'study. Pre-existing conditions, such as illnesses, symptoms, reactions, progression of', 'disease states, and other comorbidities, as well as laboratory/diagnostic test', \"abnormalities, will be documented in the patient's record as medical history.\", 'Signs and symptoms will be reported individually as adverse events (non-serious), unless', 'a medical diagnosis was provided. Medical diagnosis, whenever provided, will be', 'reported rather than individual signs and symptoms.', 'Any adverse event that satisfies any of the seriousness criteria described below will be', 'reported as an SAE using the SAE Report Form, in addition to documenting in the eCRF.', 'Serious adverse events that occurred up to 30 days after the last dose of study drug need', 'to be documented on an SAE Report Form if they are deemed by the Investigator to be', '\"Related\" to study drug.', 'Adverse Event Severity Assessment', 'The Investigator will assess the severity (ie, intensity) of each adverse event (serious and', 'non-serious) reported during the study based on his/her clinical judgment. The severity', 'of each adverse event will be assigned to one of the following categories:', 'Mild:', 'Transient, requires no special treatment, is easily tolerated by the', 'patient, causes minimal discomfort, and does not interfere with the', \"patient's daily activities\", 'Moderate:', 'Introduces a level of inconvenience or concern to the patient that may', 'interfere with daily activities, but usually is ameliorated by simple', 'therapeutic measures', 'Severe:', \"Interrupts a patient's usual daily activity and requires systemic drug\", 'therapy or other treatment', 'Definition of Serious Adverse Events', 'An SAE is any untoward medical occurrence that:', 'Results in death;', 'Is life-threatening;', 'NOTE: The term \"life-threatening\" in the definition of \"serious\" refers to an', 'event in which the patient was at risk of death at the time of the event; it does', 'not refer to an event which hypothetically might have caused death if it were', 'more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization;', 'Results in persistent or significant disability/incapacity; or', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 52 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 51 of 92', 'CR845-CLIN3102', 'Is a congenital anomaly/birth defect.', 'Medical and scientific judgment should be exercised in deciding whether expedited', 'reporting is appropriate in other situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization, but may jeopardize', 'the patient or may require intervention to prevent one of the other outcomes listed in the', 'definition above. These are usually considered serious.', 'Severe versus Serious Adverse Event', 'The term \"severe\" is used to describe the intensity (severity) of a specific event (as in', 'mild, moderate, or severe myocardial infarction); the event itself, however, may be of', 'relatively minor medical significance (such as severe headache). An adverse event as', 'well as an SAE must be assessed for severity. An adverse event that is assessed as severe', 'should not be confused with an SAE. \"Severity\" is not the same as \"Serious,\" which is', 'based on patient outcome or reaction criteria usually associated with events that pose a', \"threat to a patient's life or functioning. Seriousness (not severity) serves as a guide for\", 'defining regulatory reporting obligations.', 'Adverse Event Causality or Relatedness to the Study Drug', 'Every effort should be made by the Investigator to explain each adverse event and assess', 'its relationship, if any, to study drug. The Investigator should consider many factors,', 'including, but not limited to, temporal association of the event and date/time of study', 'drug, duration of study drug, medical/biologic plausibility, pharmacology and adverse', 'event profile of study drug, medical history (past medical history, underlying disease,', 'comorbidities, intercurrent illness), concomitant medications, medical judgment,', 'dechallenge, rechallenge, drug interaction, other plausible causes, etc., to determine the', 'causality assessment of an event.', 'The Investigator as well as the Sponsor will determine adverse event/SAE causality as', '\"Related\\' or \"Not Related\\' to study drug. Although there is no international consensus on', 'how to define \"Related\\' and \"Not Related, in general, an event is considered \"Related\\' if', 'there is reasonable possibility that the event is related to study drug than to any other', 'possible cause(s). Conversely, an event is considered \"Not Related\\' if there is reasonable', 'possibility that the event is related to other factors than the study drug.', 'Adverse Event Documentation and Follow-up', 'All adverse events, including observed, elicited, or volunteered problems, complaints, or', \"symptoms are to be recorded on the adverse event page in the patient's eCRF from the\", 'time the patient signs the ICF and until the Follow-up Visit/early termination, whether or', 'not judged by the Investigator to be related to study drug. The need to capture this', 'information is not dependent upon whether adverse events are related to study drug.', 'Serious adverse events that occurred up to 30 days after the last dose of study drug need', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 53 of 95']\n\n###\n\n", "completion": "END"}